The American Journal of Managed Care: Diagnostic and Patient Education Strategies in ITP A panelist discusses how ITP diagnosis remains one of exclusion requiring thorough testing to rule out other causes of thrombocytopenia, followed by patient education about autoimmune diseases and ... Immune thrombocytopenia (ITP) is a chronic autoimmune disorder associated with platelet destruction and increased bleeding risk, substantial economic burden, and impairment of health-related quality ... Novel treatment targets BTK through multi-immune modulation to help address the underlying causes of ITP Approval based on the LUNA 3 phase 3 study that demonstrated rapid and durable platelet ...
Monthly Prescribing Reference: Ianalumab Significantly Prolongs Time to Treatment Failure in Primary ITP Sanofi SNY announced that the FDA has approved Wayrilz (rilzabrutinib), a novel BTK inhibitor, for the treatment of persistent or chronic immune thrombocytopenia (ITP) in adult patients who have had ... Medscape: Upfront Therapy for ITP in Kids: New Drug a Game Changer? Children with newly diagnosed immune thrombocytopenia (ITP) treated with eltrombopag as a frontline therapy show significantly improved platelet responses and other outcomes compared with the standard ...
